Cadila Healthcare gets EIR from USFDA for Baddi facility
New Delhi: Drug firm Cadila Healthcare on Thursday said its Baddi facility in Himachal Pradesh has received establishment inspection report (EIR) from the US health regulator. "The company's formulations manufacturing facility located at Baddi, India, has received an EIR. The United States Food and Drug Administration (USFDA) had conducted an inspection at the facility from July 15 to 19, 2019," Cadila Healthcare said in a filing to BSE.
Read Also: Cadila Healthcare arm gets USFDA nod for Haloperidol Decanoate injection to treat schizophrenia
The EIR report stated that the classification of the facility is 'No Action Indicated (NAI)', it added.
Read Also: Cadila Healthcare largest API manufacturing site clears USFDA inspection
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd